EnsoData
EnsoData is a Madison, Wisconsin-based healthcare AI company that builds FDA-cleared software for sleep medicine, including AI sleep scoring, multi-night home sleep testing, and therapy monitoring. Its platform serves 500+ sleep clinics and has supported 2.9 million patients.
- Company typePrivate
- Founded2015
- HeadquartersMadison, United States
- Headcount101–250
- GTM typeB2B
- OfferingSoftware
What EnsoData does
EnsoData is a Madison, Wisconsin-based healthcare technology company founded in 2015 that develops FDA-cleared AI software for sleep medicine diagnostics and therapy monitoring. Its core platform is EnsoHub, a cloud-based unified environment that ingests and analyzes photoplethysmography (PPG) signals from FDA-cleared wearable pulse oximeters, alongside flow, snore, respiratory effort, SpO2, heart rate variability, actigraphy, position, and acoustic data channels. EnsoSleep provides AI-assisted scoring of polysomnography (PSG) and home sleep apnea tests (HSAT), achieving AASM Autoscoring Certification and delivering 62%+ time savings on PSGs and 68%+ on HSTs; EnsoHST enables multi-night home sleep testing of up to seven nights per patient with 92%+ sensitivity for sleep apnea detection; Therapy Track extends the platform into long-term monitoring and at-home titration across CPAP, HGNS, oral appliances, and GLP-1s; and the Celeste+ mobile app provides the patient-facing setup and data capture layer.
The company monetizes primarily through per-patient SaaS pricing for EnsoSleep AI scoring and EnsoHST multi-night testing, complemented by licensing/royalty arrangements such as its Takeda collaboration for narcolepsy type 1 AI algorithms and its acquisition of Resonea's acoustic diagnostic technology. It sells through an enterprise direct sales motion led by Chief Commercial Officer Bobby Cockrill and a parallel channel partner model with device manufacturers (BodiMetrics, Nonin, Viatom, Advanced Brain Monitoring, Happy Health) and healthcare providers (Aeroflow Sleep, Blackstone Medical Services, React Health). EnsoData serves 500+ sleep clinics and health systems, has supported care for 2.9 million patients, and processes 100,000+ patients monthly.
EnsoData is venture-backed, having raised $20M Series B led by Questa Capital in June 2025 and additional growth capital from CIBC Innovation Banking in May 2026, with earlier rounds led by Inspire Medical Systems and others. Strategic investors include Inspire Medical Systems and Takeda, and the company holds multiple certifications including four FDA 510(k) clearances, ISO 13485/MDSAP, HITRUST, and SOC 2 Type II. The business model is a vertically integrated AI sleep medicine platform spanning diagnostics, AI scoring, multi-night testing, and therapy monitoring, with regulatory and data assets serving as the primary competitive moats.
EnsoData firmographics
Firmographics- Name
- EnsoData
- Legal name
- EnsoData, Inc.
- Website
- https://ensodata.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- EnsoData is a Madison, Wisconsin-based healthcare AI company that builds FDA-cleared software for sleep medicine, including AI sleep scoring, multi-night home sleep testing, and therapy monitoring. Its platform serves 500+ sleep clinics and has supported 2.9 million patients.
- Ownership category
- akta.pro rank
EnsoData industry classification
Industry- Product category
- AI Sleep Diagnostics Software
- NAICS
- Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (5182)
- SIC
- Services-Prepackaged Software (7372), Services-Computer Programming Services (7371)
- akta.pro primary industry
- Sleep Diagnostics & Monitoring (PSG/Home Sleep Testing, Actigraphy) (HLAHAGAB)
- akta.pro secondary industries
- Respiratory & Sleep RPM (COPD, asthma, sleep apnea) (HLALAFAB), Pulmonology & Sleep Medicine Telemedicine Platforms (HLALAGAF), eCOA/ePRO/eDiary & Patient-Facing Data Collection (HLACAOAB)
Keywords
Where EnsoData is headquartered
LocationHeadquarters
- HQ city
- Madison
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
EnsoData business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Revenue model
- EnsoHST Per-Patient Pricing: One flat price per patient for up to 7 nights of home sleep testing. No upfront device costs, no expensive disposables, no device return required for results. Includes AI analysis, cloud platform access, and report generation.
- EnsoSleep AI Scoring: Cloud-based AI scoring subscription for sleep labs. Integrates with existing PSG and HSAT devices and software. Pricing based on study volume with time savings enabling scalability.
- Technology Acquisition (Resonea): Acquired sleep testing diagnostic technology from Resonea to enhance home sleep testing with acoustic flow and microphone data channels. Expected US commercial availability within 2024.
- Takeda Collaboration: Collaboration with Takeda to develop AI-based PSG algorithms for narcolepsy type 1 diagnosis. Upon successful validation and regulatory clearance, algorithms will be integrated into EnsoSleep platform.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | EnsoHST Multi-Night Testing - One flat fee per patient for up to 7 nights |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels9 records
EnsoData product offering
Product offeringCore offering
EnsoData develops and sells FDA-cleared AI/ML-powered software for sleep medicine diagnostics and therapy monitoring. Its core offerings include EnsoHST (multi-night home sleep testing), EnsoSleep (AI-assisted PSG and HSAT scoring), EnsoHub (unified cloud-based study management platform), and Therapy Track (long-term therapy monitoring). The platform analyzes physiological signals from third-party pulse oximeters to deliver automated sleep apnea detection, scoring, and reporting for sleep clinics and health systems.
Product overview
EnsoData offers a unified AI-powered ecosystem for sleep medicine diagnostics and therapy management. The core platform consists of EnsoHST (multi-night FDA-cleared home sleep testing), EnsoSleep (AI-assisted scoring for PSGs and HSATs), and EnsoHub (cloud-based unified study management platform). These products work together to power the complete sleep care journey from diagnosis through long-term therapy monitoring. EnsoHST leverages photoplethysmography signals from wearable pulse oximeters to enable affordable, patient-friendly multi-night testing while EnsoSleep provides automated scoring analysis. Therapy Track extends the ecosystem to long-term therapy monitoring. The system integrates with third-party pulse oximetry devices (BodiMetrics, Nonin, Viatom), ePrescribing platforms (Parachute Health), and therapy devices (React Health) to create a comprehensive connected care solution.
Differentiator
Problem solved
Functional benefit
Brands
- EnsoHST: FDA-cleared, multi-night home sleep testing solution that leverages PPG signals from wearable pulse oximeters to deliver fast, reliable, and comprehensive sleep disorder diagnostics. Enables testing for up to 7 nights per patient with AI-powered analysis.
- EnsoSleep
- EnsoHub
- Therapy Track
- Celeste+ (Mobile App)
Products and services
- EnsoHST FDA-cleared multi-night home sleep testing (HSAT) solution that analyzes photoplethysmography (PPG) signals from wearable pulse oximeters to automatically score sleep apnea events. Supports up to 7 nights of testing per patient with AI-driven analysis available within minutes of study completion. Clinically validated with 92%+ sensitivity for sleep apnea and 97% patient success rate.
- EnsoSleep FDA-cleared AI-assisted sleep scoring and analysis solution for polysomnographies (PSGs) and home sleep apnea tests (HSATs). Automates detection of sleep-disordered breathing, sleep staging, and generates diagnostic reports. Achieves 93% diagnostic AHI agreement and 86% sleep staging agreement with gold-standard manual scoring, with AASM Autoscoring Certification achieved in April 2024.
- EnsoHub Cloud-based unified platform for accessing, reviewing, editing, and reporting on all AI-scored HSAT, PSG, and PPG-based sleep studies across all locations, devices, and sleep techs. Centralizes study management with professional, clinic-branded reports that auto-update with physician edits, eliminating the need for VPNs.
- Therapy Track Long-term therapy monitoring and titration solution that extends the sleep care pathway from diagnostic testing through ongoing treatment. Monitors CPAP, HGNS, oral appliances, GLP-1s, and emerging therapies using the same devices used for diagnostic testing, enabling at-home therapy titration without repeat in-lab studies.
- Celeste+ Mobile App Patient-facing FDA-cleared mobile application for EnsoHST multi-night home sleep testing. Guides patient setup with connected pulse oximetry devices, automatically uploads data upon study completion, and provides immediate confirmation or guidance to test additional nights. Includes Acoustic Flow, Snore, and Actigraphy channels.
Quantifiable outcome
- 92%+ sensitivity for Sleep Apnea detection
- +10 more outcomes
Companies that use EnsoData
Customer profileNamed customers9 records
Segments4 records
Ideal customer profiles3 records
EnsoData technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration6 records
AI capability9 records
Feature8 records
EnsoData partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered strategic, core and minor.
- Takeda PharmaceuticalsstrategicCollaboration to develop and validate AI-based PSG algorithms for narcolepsy type 1 (NT1) diagnosis. Upon successful validation and regulatory clearance, algorithms will be integrated into EnsoSleep platform for clinical availability.
- ResoneacoreAcquisition of sleep testing diagnostic technology from Resonea to enhance home sleep testing with acoustic flow and microphone data channels. Includes FDA-cleared mobile app technology for pre-screening and diagnosis.
- React HealthstrategicPartnership in October 2023 to improve patient adherence to sleep apnea therapy through AI-powered monitoring and predictive analytics.
- Aeroflow SleepstrategicAeroflow Sleep partnership to deploy EnsoData's predictive AI for proactive sleep apnea management across the United States.
- Happy HealthminorPartnership to simplify at-home diagnosis and treatment monitoring of patients with sleep apnea, reducing barriers to care by putting patients in control of their health journey.
- Blackstone Medical ServicesminorPartnership to address the 80% of undiagnosed sleep apnea cases through Blackstone's medical services and EnsoData's diagnostic technology.
Scale indicators12 records
Recent moves6 records
Expansion highlights7 records
EnsoData competitors and assessment
Company assessmentBroad incumbents
- ResMed: Global leader in sleep apnea and respiratory care devices (CPAP, masks) with growing digital health software (myAir, AirView) for therapy monitoring. Comparable to EnsoData as both target the sleep apnea care continuum, though ResMed operates upstream in therapy hardware rather than diagnostics AI.
- BMC Medical: Chinese sleep and respiratory device manufacturer with global HSAT and CPAP footprint. Competes in the same clinical channel (sleep labs) with hardware-centric approach, contrasting with EnsoData's hardware-agnostic AI platform model.
Direct peers
- Itamar Medical (WatchPAT): ZOLL Itamar Medical makes WatchPAT, a proprietary home sleep apnea testing device with embedded AI-driven autoscoring. Direct competitor to EnsoHST in the HSAT market, with similar FDA-cleared automated scoring positioning.
- Nox Medical: Iceland-based manufacturer of PSG and HSAT hardware (Noxturnal software) with AI-assisted scoring capabilities. Competes with EnsoData in the sleep diagnostics market, particularly for in-lab PSG and home sleep testing workflows.
- CleveMed: U.S. medical device company offering home sleep testing devices (SleepView) and cloud-based sleep scoring services. Direct competitor in the HSAT and AI-assisted scoring space, with comparable clinic-targeted sales motion.
- Compumedics: Australia-based sleep diagnostics company offering PSG and HSAT hardware with Profusion software. Competes in EnsoData's FDA-cleared Australia/Canada markets with integrated hardware + scoring solutions.
Others
- Inspire Medical Systems: Medical device company behind Inspire UAS therapy for sleep apnea (investor and board seat in EnsoData via CTO John Rondoni). Adjacent in the sleep apnea care continuum, providing HGNS therapy data that integrates with EnsoData's diagnostic and monitoring platform.
- React Health: Respiratory and sleep therapy device company (CPAP, masks) partnered with EnsoData since October 2023 to improve therapy adherence via AI monitoring. Comparable in targeting the same sleep apnea patient population but with therapy hardware rather than diagnostic AI.
Emerging players
- Cerebra Health: Canadian sleep diagnostics AI company offering automated PSG scoring software with comparable clinical validation and time-savings positioning. Direct emerging competitor in the AI sleep scoring category.
- Sana Health: Digital health company applying AI and multimodal data to sleep and pain management. Comparable in applying AI to sleep medicine use cases but with adjacent therapeutic focus rather than diagnostic scoring.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
EnsoData social profiles
Digital presenceEnsoData compliance and trust
Trust signalCompliance6 records
EnsoData financial estimates
Financial estimateRevenue estimate
Valuation estimate
EnsoData leadership team
Management profileNumber of profiles
Profiles20 records
EnsoData funding detail
Funding detailFunding overview
Funding rounds9 records
Investors17 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
EnsoData M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about EnsoData
What does EnsoData do?
EnsoData develops and sells FDA-cleared AI/ML-powered software for sleep medicine diagnostics and therapy monitoring. Its core offerings include EnsoHST (multi-night home sleep testing), EnsoSleep (AI-assisted PSG and HSAT scoring), EnsoHub (unified cloud-based study management platform), and Therapy Track (long-term therapy monitoring). The platform analyzes physiological signals from third-party pulse oximeters to deliver automated sleep apnea detection, scoring, and reporting for sleep clinics and health systems.
Is EnsoData a public or private company?
EnsoData is a private company. It is classified as venture growth investor backed and is currently operating.
When was EnsoData founded?
EnsoData was founded in 2015. It employs 101 to 250 people.
Where is EnsoData based?
EnsoData is headquartered in Madison, United States, in the North America region.
How does EnsoData make money?
Four revenue lines are on record. EnsoHST Per-Patient Pricing is the primary driver. The others are ensoSleep AI Scoring, technology Acquisition (Resonea) and takeda Collaboration.
Who are EnsoData's main competitors?
Broad incumbents on record are ResMed and BMC Medical. Direct peers are Itamar Medical (WatchPAT), Nox Medical, CleveMed and Compumedics. Others are Inspire Medical Systems and React Health. Emerging players are Cerebra Health and Sana Health.
Does EnsoData have an API?
No public API is recorded for EnsoData.
What industry is EnsoData in?
EnsoData's product category is AI Sleep Diagnostics Software. Its primary akta.pro industry code is HLAHAGAB, Sleep Diagnostics & Monitoring (PSG/Home Sleep Testing, Actigraphy), with a secondary code of HLALAFAB, Respiratory & Sleep RPM (COPD, asthma, sleep apnea). Its NAICS code is 5182 and its SIC code is 7372.